Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis
Authors:
Open Access
- 1 January 2021
- journal article
- review article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 12 (4) , 1133-1143
Abstract
Purpose: The clinical use of immunotherapies targeting programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) is rapid expanding, but the equivalency of these inhibitors remains unclear. We aimed to comprehensively compare the efficacy and safety of PD-1/PD-L1 inhibitors with a systematic review and Bayesian network meta-analysisKeywords
This publication has 48 references indexed in Scilit:
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2015
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated MelanomaNew England Journal of Medicine, 2015
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialThe Lancet Oncology, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysisThe Lancet Oncology, 2013
- Comparing Bayesian and Frequentist Approaches for Multiple Outcome Mixed Treatment ComparisonsMedical Decision Making, 2013
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- B7-H1 is a ubiquitous antiapoptotic receptor on cancer cellsBlood, 2008
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007